Patients with PSA below 0.2 ng/mL at 8 years post high-dose-rate brachytherapy have an extremely low risk of subsequent recurrence.
Int J Urol
; 30(12): 1147-1154, 2023 Dec.
Article
in En
| MEDLINE
| ID: mdl-37650359
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Prostatic Neoplasms
/
Brachytherapy
Type of study:
Etiology_studies
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Humans
/
Male
Language:
En
Journal:
Int J Urol
Journal subject:
UROLOGIA
Year:
2023
Type:
Article
Affiliation country:
Japan